Background
and study aim: Dermatological adverse events are an existing concern during treatment of chronic hepatitis C virus infection. Pegylated Interferon (peg -IFN-alfa2a) and ribavirin combination therapy is associated with well-characterized dermatological lesions tending towards a uniform entity of dermatitis. A prospective observational study was designed to evaluate the frequency and clinical pattern of cutaneous side effects in a cohort of patients receiving combination therapy of (pegylated interferon alfa2a) and ribavirin for chronic hepatitis C infection.
Patients and Methods:
This study was carried out at Alahrar Center for treating chronic hepatitis C patients which is one of the centers of the national committee for treating chronic hepatitis C patients (HCV), Zagazig, Sharkia governorate, Egypt over a period of one year starting from January, 2014 to December 2014. A cohort of 116 consecutive, HCV-positive patients to be treated with pegylated interferon alfa2a and ribavirin with standard doses, were prospectively enrolled. After taking an informed consent, detailed history and cutaneous examination, before treatment and then monthly follow up for one year(during the course of treatment) were performed and recorded .All patients were subjected to throughout, routine laboratory investigations before enrollment including, CBC, random blood sugar, complete liver and renal function tests, TSH, Alfa fetoprotein, antibilharzial Ab titre, ANA, P.T, INR, quantitative PCR for HCV-RNA, pregnancy test was performed for the ladies.
Results: 113/116 patients (97%) experienced 1 or more cutaneous side effects. The most frequent was hair loss and occurred in 69 cases (61%). Pigmented Oral lichen planus was noted in 50 cases (43%) and generalized pigmentation in 32 (27%). Hypertrichosis of eyelashes (trichomegaly) and eyebrows (synophyrs) was observed in 42 (36%) and 40 (34%) cases respectively. Pruritus occurred in 50 cases (43%), aphthous stomatitis was observed in 33 cases (38%), 19 patients (22%) either developed or had worsening of melasma and 23 (27%) developed urticaria. Brittle nails (10 cases), cheilitis (8 cases), glossitis (3 cases), actinic lichen planus (9 cases), greying of hair (3 cases), discoloration of moustache hair (1 case), and photosensitivity (3 cases) were also observed. Preexisting psoriasis (8 cases), and lichen planus (5 cases) aggravated. Eruptive seborrhoeic keratosis was reported in 1 case.
Conclusion:
113/116 patients (97%) experienced 1 or more cutaneous side effects. The most frequent was hair loss and occurred in 69 cases (61%). Pigmented Oral lichen planus was noted in 50 cases (43%) and generalized pigmentation in 32 (27%). Hypertrichosis of eyelashes (trichomegaly) and eyebrows (synophyrs) was observed in 42 (36%) and 40 (34%) cases respectively. Pruritus occurred in 50 cases (43%), aphthous stomatitis was observed in 33 cases (38%), 19 patients (22%) either developed or had worsening of melasma and 23 (27%) developed urticaria. Brittle nails (10 cases), cheilitis (8 cases), glossitis (3 cases), actinic lichen planus (9 cases), greying of hair (3 cases), discoloration of moustache hair (1 case), and photosensitivity (3 cases) were also observed. Preexisting psoriasis (8 cases), and lichen planus (5 case) aggravated. Eruptive seborrhoeic keratosis was reported in (1 case).
INTRODUCTION
The incidence of HCV on a global scale as many as 2 to 3millions persons may be chronically infected in the United States, 5 to 10 millions in Europe, and about 12 millions in India, and most do not know they are infected. About 150 000 new cases occur annually in the US and in Western Europe, and about 350 000 in Japan. Of these, about 25% are symptomatic, but 60 to 80% may progress to chronic liver disease, and 20% of these develop cirrhosis. About 5%-7% of patients may ultimately die from the sequalae of the infection [1].
Most European countries report a prevalence of HCV in the general population of between 0.5 and 2%.WHO estimates that about 3% of the world's population has been infected with HCV and that there are more than 170 million chronic carriers who are at risk of developing liver cirrhosis and/or liver cancer. Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated nationally at 14.7% The purpose of this study was to assess the frequency and clinical pattern of cutaneous side effects in patients receiving combination therapy (peg-INF-α2a) and ribavirin for chronic hepatitis C.
PATIENTS AND METHODS
One hundred and sixteen HCV positive patients were enrolled in this study.
Diagnosis of HCV was based on detection of serum HCV-RNA by quantitative polymerase chain reaction (PCR). All patients received combination therapy of pegylated interferon alfa2a and oral ribavirin, both were administered at standard doses, for one year [3] . The standard combination dose regimen was (peg-IFN-alfa2a, 180 mcg/ once/week) and ribavirin (1,000 -1,200 mg/day depending on whether body weight was below or above 75 kgs.). Dose modifications of INF and/or ribavirin were performed, as indicated by the presence of adverse effects or hematological abnormalities.
Skin, mucous membranes, hair and nails were examined before starting treatment and there after, monthly till the treatment was completed. Preexisting lesions were documented on starting treatment and were observed subsequently on each visit.
Laboratory assessment included Hb%, WBC, platelet count, TSH, billirubin, ALT, AST and alkaline phosphatase on starting therapy and then monthly. 
RESULTS
A total of 116 patients, 70 females and 46 males were observed over a period of one year (whole course of therapy).
Age of the patients ranged from 21 to 53 years (mean age 35 yrs). The type and frequency of skin manifestations are shown in Tables 1 and 2 . The most frequently observed cutaneous manifestations involved hair and the oral cavity.
Effect of this therapeutic combination on hair was rather interesting. On one hand there was diffuse thinning of scalp hair and on the other, significant eyelash and eyebrow hypertrichosis was noted. Loss of hair was also noted at the site of subcutaneous injections of pegylated INF-α2a (Fig. 1) .
Asymptomatic tongue pigmentation of a peculiar type was noted in a significant number of patients. Hyperpigmentation was in the form of streaks on each side of the tongue in most patients
Oral biopsy was performed to rule out lichen planus in patients who complained of burning in the oral cavity along with pigmentation. Pigment abnormality as generalized darkening of complexion, appearance or darkening of preexisting melasma was a common complaint. Nail pigmentation involving either the whole nail or only lunulae was observed. The number of nails involved also varied. One patient developed white bands on nails (Mee's lines) which are frequently seen in patients with chronic disease. Lichen planus developed in 5 patients towards the end of treatment.
Apart from effects on skin and adenexa a number of extracutaneous effects were also noted (Table  3) . Flu-like symptoms and generalized aches and pains lasted from 12 to 48 hours following interferon injection. The intensity of these symptoms was most pronounced following the initiation of therapy. During the treatment period patients complained of feeling of being unwell and loss of interest in daily activities. Forgetfulness, irritability, anger/ hostility and depression were some of the other complaints. A single patient developed psychosis preceded by depression after start of therapy.
None of the cutaneous effects were severe enough to warrant discontinuation of treatment. Alopecia, eyelash and eyebrow hypertrichosis, greying and lightening of hair was observed in our study. Loss of hair started within the first month of the treatment and continued throughout the therapy. Hair disorders have been frequently described with peg-IFN-α2a therapy. In our study, diffuse thinning of scalp hair and eyelash and eyebrow hypertrichosis was observed in a large proportion of patients. While thinning of scalp hair was commoner in females, eyelash and eyebrow hypertrichosis was more frequent in males. Eyelid and eyebrow trichomegaly has been reported earlier, with this combination in only a few case reports [20] .
The development of pigmentation during treatment with peg-interferon α2a and ribavirin is not associated with any specific genotype of hepatitis virus C, dose or duration of interferon or ribavirin treatment, or response to treatment [22] . Pigmentation usually increases up to the end of treatment and tends to partially resolve after discontinuation of treatment. However, there are no reports of complete resolution of lesions in the long-term. Although oral lesions may cause subjective discomfort, this is not severe and it is not recommended to discontinue treatment [27].
Hyperpigmentation of oral mucosa associated with peg-interferon-α2a and ribavirin combination therapy for hepatitis C was first described by The high incidence of pigmentary disturbances i.e. oral pigmentation, darkening of complexion, melasma and nail pigmentation in our patients could be related to the predominant Fitzpatrick skin type IV and V in this part of the world. However, the reason for the peculiar linear distribution of hyperpigmentation like the opposite effect of hair loss at one place and growth at other, pigment deposition increases in skin but seems to have quite the opposite effect on hair, producing greying of hair and discoloration of moustaches [28] .
Nail discoloration in our patients followed different patterns. Mostly discoloration of all nails was noted. In some patients one or two nails, toe nails or only the lunulae were involved. Pigmentation of nails was also observed as linear or horizontal streaks.
Occurrence of vitiligo in patients with hepatitis on peg-IFN-α2a therapy has been reported to occur as early as one month. Depression has been observed with this therapeutic combination [40] . peg-IFN-α2a treatment modulates the serotoninergic system through cytokine production. It has been shown to decrease tryptophan availability for serotonin synthesis and also modify central serotoninergic receptors [41] . It is recommended that it should be taken into account and a close eye be kept on psychological issues.
CONCLUSION
A number of cutaneous manifestations were noted in the patients receiving combination therapy of peg-INF-α2a plus ribavirin for chronic hepatitis C. The most frequent and distressing for the patients were the effects on hair. However, none of the cutaneous effects were severe enough to warrant discontinuation of therapy. Awareness of these cutaneous side effects may be useful for the dermatologist to counsel the patients receiving this treatment. A prolonged follow up is required to see when, or if at all, any of these adverse effects settles down after discontinuation of treatment.
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